A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Recruiting

Phase 1

Phase 2

GI-102, Pembrolizumab, T-DXdA Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)

Sponsor:

GI Innovation, Inc.

Code:

NCT05824975

Conditions

Advanced Solid Tumor

Metastatic Solid Tumor

Soft Tissue Sarcoma (STS)

Platinum-resistant Ovarian Cancer (PROC)

Hepatocellular Carcinoma (HCC)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

GI-102 subcutaneous (SC)

GI-102

doxorubicin

paclitaxel

bevacizumab

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-06-01. This information was provided to ClinicalTrials.gov by GI Innovation, Inc. on 2024-11-25.